home
Author : adminDate : 2023-05-23 15:02

FDA Approval Sought for Frontline Camrelizumab Plus Rivoceranib in uHCC

A new drug application (NDA) has been submitted to the FDA, seeking approval of rivoceranib in combination with camrelizumab (SHR-1210) for the frontline treatment of patients with unresectable hepatocellular carcinoma (uHCC).1 


Please refer to the following website for further details: FDA Approval Sought for Frontline Camrelizumab Plus Rivoceranib in uHCC (targetedonc.com)